SLGL (Sol-Gel Technologies) Total Current Liabilities: $6.31 Mil (As of Mar. 2026)


SLGL Sol-Gel Technologies Ltd SLGL
56 GF Score
Price $73.50
GF Value $65.37
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Sol-Gel Technologies Total Current Liabilities?

Sol-Gel Technologies SLGL +1.87% 56 Total Current Liabilities is $6.31 Mil as of Mar. 2026. GuruFocus rates SLGL with a GF Score™ of 56/100 and a GF Value™ of $65.37 (Modestly Overvalued). The stock has 2 warning signs investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Sol-Gel Technologies's total current liabilities for the quarter that ended in Mar. 2026 was $6.31

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Sol-Gel Technologies Total Current Liabilities Related Terms

Sol-Gel Technologies Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for Sol-Gel Technologies's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sol-Gel Technologies Total Current Liabilities Chart

Sol-Gel Technologies Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.69 3.33 4.52 5.29 6.17

Sol-Gel Technologies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.57 4.96 6.15 6.17 6.31
SLGL
56GF Score
Sol-Gel Technologies Ltd SLGL
Total Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sol-Gel Technologies Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Sol-Gel Technologies's Total Current Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=5.676+0.495
+Other Current Liabilities+Current Deferred Liabilities
=0+0
=6.17

Sol-Gel Technologies's Total Current Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=5.828+0.485
+Other Current Liabilities+Current Deferred Liabilities
=-8.8817841970013E-16+0
=6.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of $6.31 Mil mean?
Sol-Gel Technologies (SLGL) has a Total Current Liabilities of $6.31 Mil as of Mar. 2026. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Sol-Gel Technologies and its competitors.
Is Sol-Gel Technologies' Total Current Liabilities too high?
Sol-Gel Technologies' current Total Current Liabilities is $6.31 Mil. Overall, Sol-Gel Technologies has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sol-Gel Technologies' Total Current Liabilities compare to ALEC and LENZ?
Sol-Gel Technologies' Total Current Liabilities of $6.31 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Biotechnology company?
A good Total Current Liabilities depends on the Biotechnology industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Sol-Gel Technologies and its competitors. Sol-Gel Technologies's current Total Current Liabilities is $6.31 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sol-Gel Technologies stock overvalued right now?
Based on GuruFocus' analysis, Sol-Gel Technologies (SLGL) is currently considered Modestly Overvalued. The stock's GF Value™ is $65.37, compared to a current price of $73.50 — trading 12.4% above its estimated fair value. The current Total Current Liabilities is $6.31 Mil. Sol-Gel Technologies' overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Sol-Gel Technologies (SLGL), the current Total Current Liabilities is $6.31 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sol-Gel Technologies (SLGL) Overvalued in 2026?

Based on GuruFocus' analysis, Sol-Gel Technologies stock appears to be overvalued. The current stock price of $73.50 is trading 12.4% above its estimated GF Value™ of $65.37. GuruFocus considers Sol-Gel Technologies to be Modestly Overvalued.

Key valuation signals for SLGL:

  • Total Current Liabilities: $6.31 Mil
  • GF Value™: $65.37 vs. price of $73.50 (12.4% above fair value)
  • GF Score™: 56/100 with 2 warning signs

No single metric tells the full story. See the SLGL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sol-Gel Technologies Business Description

Other Exchanges 4SG:Germany
Address 7 Golda Meir Street, Weizmann Science Park, Ness Ziona, ISR, 7403650
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.
56GF Score

Get the complete analysis for SLGL

Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$73.50
Price
$65.37
GF Value